CRISPR Therapeutics Vertex Pharmaceuticals: Better Buy in 2026
Investors face a choice between a high-growth gene-editing bet and a cash-generating biotech leader. This article bre...
Identify index funds with top risk-adjusted returns to guide smarter allocations. Learn criteria for selecting high-efficiency funds.
28,465 articlesInvestors face a choice between a high-growth gene-editing bet and a cash-generating biotech leader. This article bre...
The latest Freddie Mac survey shows the 30-year fixed rate dipping under 6% for the first time in years, signaling po...
April data from the Mortgage Bankers Association show a modest uptick in mortgage payments, nudging homebuyer afforda...
May consumer sentiment slips again as high gas prices squeeze household budgets. The Michigan reading signals a broad...
The social security cola forecast for 2027 climbs to 3.9%, driven by persistent inflation in housing and energy. Reti...
In a speculative timeline, Kevin Warsh is named Federal Reserve Chair, prompting a rethink of policy amid AI-driven g...
NVIDIA CEO Jensen Huang's praise for Marvell sparks a broad rally in optical suppliers, lifting Lumentum and Coherent...
Despite a slim yield, the WisdomTree U.S. Quality Dividend Growth Fund continues to attract institutional buyers. Her...
SK Hynix moves to list American Depository Receipts on Nasdaq, broadening U.S. investor access. The plan comes as AI-...
Investors are buzzing about Uber stock soaring? as the company moves toward stronger profitability and disciplined gr...
A once-overlooked dividend ETF is delivering double-digit gains this year, signaling a shift from megacap leadership ...
The SEC approves WisdomTree's request for exemptive relief, unlocking 24/7 trading and near-instant settlement for to...